Prothena | PRTA - Assets


Prothena reported $352.63M in Assets for its fiscal quarter ending in September of 2025.





Assets Change Date
Acadia Pharmaceuticals USD 1.33B 105.22M Sep/2025
Agios Pharmaceuticals USD 1.3B 88.48M Dec/2025
Akebia Therapeutics USD 364.15M 18.56M Sep/2025
ALKERMES USD 2.33B 76.7M Sep/2025
Alnylam Pharmaceuticals USD 4.97B 114.67M Dec/2025
Amgen USD 90.59B 445M Dec/2025
Biogen USD 29.44B 232M Dec/2025
BioMarin Pharmaceutical USD 7.59B 20.85M Dec/2025
Exelixis USD 2.84B 20.87M Dec/2025
Immunic USD 40.7M 20.72M Sep/2025
Incyte USD 6.96B 627.62M Dec/2025
Ionis Pharmaceuticals USD 3.03B 47.96M Sep/2025
MacroGenics USD 270.76M 25.34M Sep/2025
Nektar Therapeutics USD 301.35M 93.81M Sep/2025
Neurocrine Biosciences USD 4.63B 365.8M Dec/2025
Prothena USD 352.63M 46.44M Sep/2025
Regeneron Pharmaceuticals USD 40.56B 389.3M Dec/2025
Ultragenyx Pharmaceutical USD 1.53B 341.56M Dec/2025
Vertex Pharmaceuticals USD 25.64B 780.7M Dec/2025
Xoma USD 263.15M 39.7M Sep/2025